Accession Therapeutics presented some of the exciting preclinical data for our lead programme
Accession Therapeutics presented some of the exciting preclinical data for our lead programme #TROCEPT-01 at the recent 37th Annual Meeting of the @Society for Immunotherapy of Cancer.
Working with our partners at @Cardiff University we demonstrated the potential of #TROCEPT products to generate high concentrations of potent anti-tumour drugs selectively in cancer cells with minimum systemic toxicity.
In in vitro and in vivo studies #TROCEPT-01 was shown to traffic to tumour cells highly selectively where its immune checkpoint inhibitor transgene was functionally expressed. Minimal levels of #TROCEPT-01 were detected outside of the tumour.
Read more about how #TROCEPT, a novel cancer-selective delivery technology, is powering our pipeline here.
@Journal for ImmunoTherapy of Cancer
Comentarios